Aprotinin treatment against SARS‐CoV‐2: a randomized phase III study to evaluate the safety and efficacy of a pan‐protease inhibitor for moderate COVID‐19

FJ Redondo‐Calvo, JF Padín… - European Journal of …, 2022 - Wiley Online Library
Background SARS‐CoV‐2 virus requires host proteases to cleave its spike protein to bind to
its ACE2 target through a two‐step furin‐mediated entry mechanism. Aprotinin is a broad …

[HTML][HTML] Interferon-γ production by CMV-specific CD8+ T lymphocytes provides protection against cytomegalovirus reactivation in critically ill patients

JJ Castón, S Cantisán, F González-Gasca… - Intensive care …, 2016 - Springer
Purpose To evaluate the usefulness of the secretion of interferon-γ (IFNγ) by
cytomegalovirus (CMV)-specific CD8+ T cells to determine the risk of CMV reactivation in …

Bictegravir/emtricitabine/tenofovir alafenamide in a multicentre cohort: real-life experience from Spain

M Torralba, G Rodríguez… - Annals of …, 2024 - journals.sagepub.com
Background: The evaluation of bictegravir, emtricitabine, and tenofovir alafenamide
(BIC/FTC/TAF) in clinical trials has shown high rates of virological suppression but …

Does fibrosis really regress in HIV/hepatitis C virus co-infected patients after treatment with direct antiviral agents?

D Rial-Crestelo, MA Sepúlveda, FJ González-Gasca… - Aids, 2020 - journals.lww.com
Objective: To evaluate the progression of liver stiffness after treatment with direct antiviral
agents (DAAs), to identify predictive factors of fibrosis regression and to analyze the …

High vancomycin minimum inhibitory concentration is associated with poor outcome in patients with methicillin-susceptible Staphylococcus aureus bacteremia …

JJ Castón, F González-Gasca, L Porras… - … journal of infectious …, 2014 - Taylor & Francis
We retrospectively investigated the impact of high vancomycin minimum inhibitory
concentration (MIC> 2 μg/ml) on the outcome of 53 patients with bacteremia caused by …

CP-132 Impact of implementing a carbapenem stewardship program

RP Serrano, AM Siguero, MP Leal, JC Osorio… - 2015 - ejhp.bmj.com
Background A carbapenem stewardship program was developed by a multidisciplinary team
of specialists in Infectious Diseases, Critical Care, Pharmacy, Microbiology and Preventive …

Impact of interferon-free therapies in HIV/HCV co-infected patients on real clinical practice: results from a multicenter region-wide cohort study (2014–2018)

D Rial-Crestelo, MA Sepúlveda… - European Journal of …, 2021 - journals.lww.com
Background Here, we assess the efficacy and safety of direct antiviral agents (DAAs) in a
real-world cohort of co-infected individuals, and evaluate the consistency between clinical …

[PDF][PDF] OR 5210 inglés Effectiveness of direct-acting antiviral therapy in patients with a HCV/HIV coinfection. A multicenter cohort study

D Rial-Crestelo, M Rodríguez-Cola… - online.reed.es
Introduction: The effectiveness of direct-acting antiviral (DAA) agents has been
demonstrated in clinical trials both in patients with mono and coinfections. The goal of the …

[CITATION][C] CP-040 Antimicrobials stewardship programme focused on long duration treatments: preliminary results

…, MT Franco-Sereno, L Porras-Leal, F González-Gasca… - 2017 - ejhp.bmj.com
WITHDRAWN BY THE EAHP ORGANISING COMMITTEE ABSTRACT WITHDRAWN BY
THE EAHP ORGANISING COMMITTEE ABSTRACT WITHDRAWN BY TH Page 1 CP-038 …

[HTML][HTML] Efectividad del tratamiento con agentes antivirales directos en pacientes con coinfección por VHC y VIH. Estudio de cohorte multicéntrico

D Rial-Crestelo, M Rodríguez-Cola… - Revista española de …, 2018 - SciELO Espana
Métodos: estudio ambispectivo multicéntrico en una cohorte de pacientes coinfectados. Los
datos fueron recogidos en ocho centros de Castilla-La Mancha entre 2014 y 2016. Se …